freeze-thaw cycling raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Brother Zachariah — formerly known as James "Jem" Carstairs, a Silent Brother, and the former parabatai of Will Herondale, who acts as a kind of uncle to James, Lucie and the others. He is also a first cousin to Cordelia and Alastair. Barbara Lightwood — The eldest child of Gideon Lightwood and Sophie Collins. Growing up, Barbara had the perfect Sight, the ability to see past glamours. She has an understanding with Oliver Hayward, whose family runs the York Institute. Barbara was very affectionate and protective over Thomas—to the point where he found it smothering—and was often considered more gentle than her sister. She was somewhat of a romantic, and wanted to become a dutiful wife rather than a strong Shadowhunter. During a demon attack in Regents Park, Barbara was bitten and collapsed. In her final moments, she was delirious and lashed out, clawing at Oliver who had been crying by her bedside. This unknowingly spread the infection to Oliver who fell ill and died shortly after. Thomas and the others dedicated themselves to not only making a cure but finding and putting an end to the demon attacks in her name. Eugenia Lightwood — The second child of Gideon Lightwood and Sophie Collins. Like Barbara, Eugenia was very affectionate and protective over Thomas, to the point where he found it smothering, and wants to become a dutiful wife rather than a strong Shadowhunter. She is considered stubborn and rebellious. Eugenia was seemingly dubbed "ruined" as she had apparently been found alone with a gentleman whom did not later propose to her.
In line with its role as a first line defense system, SP is released when toxicants or poisons come into contact with a range of receptors on cellular elements in the chemoreceptor trigger zone, located in the floor of the fourth ventricle of the brain (area postrema). Presumably, SP is released in or around the nucleus of the solitary tract upon integrated activity of dopamine, serotonin, opioid, and/or acetylcholine receptor signaling. NK1Rs are stimulated. In turn, a fairly complex reflex is triggered involving cranial nerves responsible for respiration, retroperistalsis, and general autonomic discharge. The actions of aprepitant are said to be entirely central, thus requiring passage of the drug into the central nervous system. However, given that NK1Rs are unprotected by a blood brain barrier in the area postrema just adjacent to neuronal structures in the medulla, and the activity of sendide (the peptide based NK1RA) against cisplatin-induced emesis in the ferret, it is likely that some peripheral exposure contributes to antiemetic effects, even if through vagal terminals in the clinical setting.
I cannot remember how they first came to be offered to us. But they were distributed in the dressing rooms. We didn't have to take them but most of the players did. The tablets were mostly white but once or twice they were yellow. They were used through the 1961–62 season and the championship season which followed it. Drug-taking had previously been virtually unnamed in the club. But once it had started we could have as many tablets as we liked. On match days they were handed out to most players as a matter of course. Soon some of the players could not do without the drugs. The club agreed that drugs had been used but that they "could not possibly have had any harmful effect." Dunlop, however, said he had become an addict. In November 1942, the Italian cyclist Fausto Coppi took "seven packets of amphetamine" to beat the world hour record on the track. In 1960, the Danish rider Knud Enemark Jensen collapsed during the 100 km team time trial at the Olympic Games in Rome and died later in hospital. The autopsy showed he had taken amphetamine and another drug, Ronicol, which dilates the blood vessels. The chairman of the Dutch cycling federation, Piet van Dijk, said of Rome that "dope – whole cartloads – [were] used in such royal quantities." The 1950s British cycling professional Jock Andrews would joke: "You need never go off-course chasing the peloton in a big race – just follow the trail of empty syringes and dope wrappers." The Dutch cycling team manager Kees Pellenaars told of a rider in his care:
Sources: en.wikipedia.org
Chinese officials described these criticisms as an attempt to politicise the study. Scientists involved in the WHO report, including Liang Wannian, John Watson, and Peter Daszak, objected to the criticism, and said that the report was an example of the collaboration and dialogue required to successfully continue investigations into the matter. In a letter published in Science, a number of scientists, including Ralph Baric, argued that the accidental laboratory leak hypothesis had not been sufficiently investigated and remained possible, calling for greater clarity and additional data. Their letter was criticized by some virologists and public health experts, who said that a "hostile" and "divisive" focus on the WIV was unsupported by evidence, and would cause Chinese scientists and authorities to share less, rather than more data.
=== Southeast Asia === Tofu is called tauhu in Malaysia and Singapore as well as tahu in Indonesia both from Hokkien tāu-hū; it is also known as taufu in Malaysia from Cantonese. Indonesia, Thailand, Malaysia, and the Philippines are major producers of tofu and have plants in many municipalities.
=== Chemical synthesis === The demand for vanilla flavoring has long exceeded the supply of vanilla beans. As of 2001, the annual demand for vanillin was 12,000 tons, but only 1,800 tons of natural vanillin were produced. The remainder was produced by chemical synthesis. Vanillin was first synthesized from eugenol (found in oil of clove) in 1874–75, less than 20 years after it was first identified and isolated. Vanillin was commercially produced from eugenol until the 1920s. Later it was synthesized from lignin-containing "brown liquor", a byproduct of the sulfite process for making wood pulp. Counterintuitively, though it uses waste materials, the lignin process is no longer popular because of environmental concerns, and today most vanillin is produced from guaiacol. Several routes exist for synthesizing vanillin from guaiacol. At present, the most significant of these is the two-step process practiced by Rhodia since the 1970s, in which guaiacol (1) reacts with glyoxylic acid by electrophilic aromatic substitution. The resulting vanillylmandelic acid (2) is then converted by 4-hydroxy-3-methoxyphenylglyoxylic acid (3) to vanillin (4) by oxidative decarboxylation.
=== Cardiovascular system === Estrogen affects certain blood vessels. Improvement in arterial blood flow has been demonstrated in coronary arteries. 17-beta-estradiol (E2) is considered the most potent estrogen found in humans. E2 influences vascular function, apoptosis, and damage during cardiac ischemia and reperfusion. E2 can protect the heart and individual cardiac myocytes from injuries related to ischemia. After a heart attack or long periods of hypertension, E2 inhibits the adverse effects of pathologic remodeling of the heart. During pregnancy, high levels of estrogens, namely estradiol, increase coagulation and the risk of venous thromboembolism.
Sources: en.wikipedia.org
== Metabolism == The following section describes the ADME (absorption, distribution, metabolism and excretion) of α-bungarotoxin. There is limited information available on the pharmacokinetics of this neurotoxin. More research is needed to be able to fully understand the metabolism of this neurotoxin inside the body. Absorption: α-bungarotoxin enters the body after envenomation into the bloodstream at the bite site. Through the venom, a mixture of proteins and different molecules enter the body. Distribution: Once in the bloodstream, α-bungarotoxin circulates throughout the body. Its distribution may be influenced by factors such as blood flow, tissue permeability, and the presence of binding proteins. Additionally, knowing it binds to nAChRs, it can be predicted where the neurotoxin would be present: neuromuscular junctions, autonomic ganglia, peripheral nerves, and adrenal medulla. One of the main locations would be also the central nervous system (CNS), including the brain. Specific regions such as the hippocampus, cortex, and basal ganglia contain these receptors. Metabolism: The metabolic pathways of this neurotoxins have not been fully understood yet, however, it is thought to be metabolised in the liver. Researching venom metabolism is challenging due to the multiple components present in it. Toxins that are not bound may undergo elimination through opsonization by the reticuloendothelial system, mainly involving the liver and kidneys, or they may undergo degradation through cellular internalization facilitated by lysosomes.
== Early life == Gemma Clair Collins was born on 31 January 1981 at Oldchurch Hospital in Romford, East London. She is the daughter of Joan Collins (née Williams; 21 February 1955 — 29 July 2026), who worked as a part-time hairdresser, and Alan Collins, the director of Unisystems Freight, an import-export shipping company. She has an older brother named Russell, who is also a director of their father's company. Shortly after her birth, the family moved from a house in Collier Row and Collins was raised in Rise Park where she attended Rise Park Infant School. Collins described her childhood as being "filled with love" and said that although money was "tight", her father still managed to take them on family holidays and said she has "very happy memories" of her early years. Collins then went on to attend Frances Bardsley Academy for Girls. She enjoyed performing arts from a young age and attended dance lessons and stage school. At the age of 14, she began attending the Sylvia Young Theatre School and successfully auditioned for a part in The Sound of Music. Collins' mother was encouraging and said she knew that her daughter would one day become famous. Collins was bullied at school for being outgoing and confident, and so following the success of her father's business, her parents decided to move her to Raphael Independent School, a private school, for her final year of education. She left school at the age of 16 with a G in GCSE Maths.
This page is a list of Russian drugs, or drugs that were developed in Russia, the former Soviet Union, and/or post-Soviet countries. Many Russian drugs are indicated for enhancing physical, mental, and/or cognitive performance, including drugs described as nootropics or cognitive enhancers, drugs combatting fatigue, so-called adaptogens or actoprotectors, and others. There have been concerns about Russian drugs in the Western world owing to allegedly lower standards of medical evidence in Russia compared to the West, for instance in the case of the Russian COVID vaccine Sputnik V. Some Russian drugs have been attempted to be repurposed and developed by pharmaceutical companies for use in the West, such as phenylpiracetam (fonturacetam), (R)-phenylpiracetam (MRZ-9547), Noopept (omberacetam), and armesocarb (the active enantiomer of mesocarb).
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.